Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. Show more
Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States
Start AI Chat
Market Cap
240.5M
52 Wk Range
$1.61 - $5.37
Previous Close
$2.81
Open
$3.57
Volume
70,221,749
Day Range
$3.55 - $4.00
Enterprise Value
232.4M
Cash
175.4M
Avg Qtr Burn
-28.75M
Insider Ownership
1.10%
Institutional Own.
87.91%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia | BLA Submission |